Spark's Hemophilia B Gene Therapy SPK9001 Packs A Punch And Saves Big Bucks
Executive Summary
A New England Journal of Medicine publication and editorial highlighted a small study of ten patients in which one infusion of Spark/Pfizer's SPK9001 gene therapy "nearly completely eliminated" the need for factor IX clotting products, saving $200,000 per patient per year.
You may also be interested in...
Installment Payments For Gene Therapy; From Luxturna To Hemophilia
Novel reimbursement scheme allowing payers to spread out the cost of an expensive gene therapy over time may get test drive with Spark's Luxturna before being used for big-market treatments for hemophilia.
Trial And Trial: Bracing For Commercialization Of Cell & Gene Therapies
As novel cell and gene therapies edge closer to the US market, reimbursement for expensive, long-lasting treatments remains uncertain. AmerisourceBergen Senior VP-Strategy & Commercialization Amy Grogg predicts the first launches will involve many different reimbursement models.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.